Black Rock Inc. Pds Biotechnology Corp Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Black Rock Inc. holds 1,867,427 shares of PDSB stock, worth $5.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,867,427

Previous 1,881,438 0.74%

Holding current value

$5.51 Million

Previous $9.35 Million 20.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$3.85 - $6.59 $53,942 - $92,332	-14,011 Reduced 0.74%	1,867,427 $7.4 Million
Q4 2023 Feb 13, 2024	BUY	$3.95 - $6.58 $307,922 - $512,943	77,955 Added 4.32%	1,881,438 $9.35 Million
Q3 2023 Nov 13, 2023	BUY	$4.8 - $6.4 $338,712 - $451,616	70,565 Added 4.07%	1,803,483 $9.11 Million
Q2 2023 Aug 11, 2023	BUY	$5.03 - $9.9 $6.4 Million - $12.6 Million	1,272,801 Added 276.63%	1,732,918 $8.72 Million
Q1 2023 May 12, 2023	BUY	$5.68 - $11.99 $44,020 - $92,922	7,750 Added 1.71%	460,117 $2.83 Million

Q4 2022 Feb 13, 2023	SELL	$4.92 - $13.2 $90,193 - $241,982	-18,332 Reduced 3.89%	452,367 $5.97 Million
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.79 $4,216 - $8,030	-1,387 Reduced 0.29%	470,699 $1.4 Million
Q2 2022 Aug 12, 2022	BUY	$3.05 - $6.68 $111,270 - $243,699	36,482 Added 8.38%	472,086 $1.72 Million
Q1 2022 May 12, 2022	BUY	$4.78 - $8.43 $20,071 - $35,397	4,199 Added 0.97%	435,604 $2.7 Million
Q4 2021 Feb 10, 2022	BUY	$7.76 - $14.35 $17,281 - $31,957	2,227 Added 0.52%	431,405 $3.5 Million
Q3 2021 Nov 09, 2021	BUY	$9.33 - $17.08 $258,963 - $474,072	27,756 Added 6.91%	429,178 $6.4 Million
Q2 2021 Aug 11, 2021	BUY	$4.35 - $12.86 $1.75 Million - $5.16 Million	401,422 New	401,422 $5.04 Million

Others Institutions Holding PDSB

# of Institutions

Shares Held

7.53M

Call Options Held

140K

Put Options Held

318K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $84M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account